ACRS - Aclaris stock surges on positive data from mid-stage rheumatoid arthritis ATI-450 trial

Aclaris Therapeutics (ACRS) shares up ~62% premarket after it announces positive preliminary top-line results from a 12-week, Phase 2a clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, in subjects with moderate to severe rheumatoid arthritis ((RA)).In the trial, 19 subjects were randomized in a 3:1 ratio and received either ATI-450, an investigational oral MK2 inhibitor, at 50 mg twice daily or placebo, in combination with methotrexate, for 12 weeks.The primary endpoint of the study was safety and tolerability with key secondary and exploratory endpoints including the disease activity scores, DAS28-CRP and ACR20/50/70, and the change from baseline in high sensitivity C-reactive protein ((hsCRP)) and relevant endogenous cytokine levels.In the trial, ATI-450 showed durable clinical activity, as defined by a marked and sustained reduction in DAS28-CRP and evaluation of ACR20/50/70 responses over 12 weeks, the company said.Aclaris expects to submit a full analysis of the Phase 2a data for publication in

For further details see:

Aclaris stock surges on positive data from mid-stage rheumatoid arthritis ATI-450 trial